Article Sidebar
Published:
Jan 11, 2025Keywords:
Article Details
While African Health Sciences has been freely accessible online there have been questions on whether it is Open Access or not. We wish to clearly state that indeed African Health Sciences is Open Access. There are key issues regarding Open Access needing clarification for avoidance of doubt:
- 1. Henceforth, papers in African Health Sciences will be published under the CC BY (Creative Commons Attribution License) 4.0 International. See details on https://creativecomons.org/)
- 2. The copyright owners or the authors grant the 3rd party (perpetually and in advance) the right to disseminate, reproduce, or use the research papers in part or in full, format/medium as long as:
- No substantive errors are introduced in the process
- Attribution of authorship and correct citation details are given
- The referencing details are not changed.
Should the papers be reproduced in part, this must be clearly stated.
- 3. The papers will be freely and universally accessible online in an easily readable format such as XML in at least one widely recognized open access repository such as PUBMED CENTRAL.
B. ABRIDGED LICENCE AGREEMENT BETWEEN AUTHORS AND African Health Sciences
I submitted my manuscript to African Health Sciences and would like to affirm that:
1.0 I am authorized by my co-authors to enter into these arrangements.
2.0 I guarantee, on behalf of self and co-authors:
- That the paper is original, and has not been published in any other peer-reviewed journal; nor is it under consideration by other journal (s). It does not infringe existing copyright or any other person’s rights
- That we are/I am the sole author(s) of the paper and with authority to enter into this agreement. My granting rights to African Health Sciences is not in breach of any other obligation
- That the paper contains nothing unlawful, or libelous. Nor anything that would constitute a breach of contract, confidence or commitment given to secrecy, if published
- That I/we have taken care to ensure the integrity of the article.
3.0 I and all co-authors, agree that the paper, if accepted for publication, shall be licensed under the Creative Commons Attribution License 4.0. (see https://creativecommons.org/)
Main Article Content
Effects of febuxostat in different doses on uric acid, inflammatory factors of serum and knee articular cavity, endothelin-1, and oxidative stress in patients with a gout-a comparative study
Abstract
Objective: The present comparative study aimed to investigate the effects of different doses of febuxostat on uric acid, inflammatory factors of serum, knee articular cavity, endothelin-1, and oxidative stress in patients with gout.
Methods: 80 cases with hyperuricemia admitted to our hospital (January 2018- March 2020) were randomly distributed into two groups. The control group was administered 40 mg of febuxostat tablets daily., whereas the treatment group was administered febuxostat tablets 80 mg daily. Data were collected from two groups of patients, including uric acid level, TNF-α levels of serum and knee articular cavity, vascular endothelial function, and complications 1 month after the intervention.
Results: After data intervention, the levels of uric acid, TNF-α levels of serum, and knee articular cavity, NO, and SOD were signifi cantly different between the treatment group and the control group (each p< 0.05). There were no signifi cant differences in abdominal pain and diarrhea, liver damage, kidney damage, acute gout, and pruritus between the two groups (p >0.05). The duration of activity disorder, pain duration, and swelling in the treatment group were signifi cantly shorter than those in the control group (p< 0.05). The uric acid level was positively correlated with serum TNF-α level (p < 0.05), and negatively correlated with NO and SOD levels (p < 0.05).
Conclusion: For hyperuricemia-induced gout patients, taking a large dose of 80 mg febuxostat daily can signifi cantly reduce the uric acid level and inflammatory response, improve vascular endothelial function, enhance antioxidant ability, and improve the clinical symptoms of patients without increasing the adverse reactions to medication.
Keywords: Febuxostat; hyperuricemia; gout; blood uric acid; serum inflammatory factors; inflammatory factors of knee articular cavity; endothelin 1; oxidative stress response.
